Operation Warp Speed has in some ways lived up to its name: The U.S. government has awarded almost $11 billion to seven different companies to develop vaccines, three of which — Moderna, AstraZeneca and Pfizer — are in late-stage trials.
Things are going according to the most aggressive schedule.
However, accelerating the development process has increased the likelihood of cronyism and undue political influence.
Today, we ask whether the White House’s defiance of the timelines that have long governed the development of vaccines is working.
Guest: Katie Thomas, a reporter at The New York Times who covers the health care sector, with a focus on the drug industry.
For more information on today’s episode, visit nytimes.com/thedaily